EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Disappearance of antiphospholipid antibodies after anti-CD19 chimeric antigen receptor T-cell therapy of B-cell lymphoma in a patient with systemic lupus erythematosus and antiphospholipid syndrome

Eleonora Friedberg, Philipp Wohlfarth, Ana Iris Schiefer, Cathrin Skrabs, Winfried Franz Pickl, Nina Worel, Philipp Staber, Ulrich Jäger, Cihan Ay

Journal of Thrombosis and Haemostasis · 2025

DOI: 10.1016/j.jtha.2024.09.024 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Journal of Thrombosis and Haemostasis, 2025. Verfasst von Eleonora Friedberg und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology and Hemostaseology, Department of Medicine I, Medical University of Vienna, Vienna, Austria. Hauptthemen laut MEDLINE: Antibodies, Antiphospholipid, Antigens, CD19, Antiphospholipid Syndrome, Lupus Erythematosus, Systemic. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Horizon 2020, Innovative Medicines Initiative, European Federation of Pharmaceutical Industries and Associations.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Antiphospholipid syndrome is an autoimmune disorder characterized by the development of spontaneous venous, arterial, or microvascular thrombosis and/or pregnancy-related complications (eg, miscarriages, fetal loss) in the presence of persistent antiphospholipid (aPL) antibodies. Current state-of-the-art treatment consists of indefinite anticoagulation with vitamin K antagonists to prevent recurrence of thrombotic events. This, however, represents only a symptom-control-oriented treatment approach. To date, no curative option eradicating aPL antibodies permanently or addressing the underlying pathomechanism has been established. Here, we report the case of a woman with systemic lupus erythematosus and antiphospholipid syndrome with triple aPL antibody-positivity who developed recurrent deep venous thrombosis. After receiving chimeric antigen receptor T-cell therapy for aggressive B-cell lymphoma, sustained eradication of all 3 aPL antibody subtypes was observed, suggesting a promising role of immunotherapies targeting anti-CD19 for the treatment of prothrombotic autoimmune disorders.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, AntiphospholipidAntigens, CD19Antiphospholipid SyndromeLupus Erythematosus, SystemicFemaleHumansImmunotherapy, AdoptiveLymphoma, B-CellReceptors, Chimeric AntigenRecurrenceTreatment OutcomeVenous ThrombosisAged

Stichwörter der Autor:innen

CAR T-cellantiphospholipid syndromeautoimmunitythromboembolic eventsthrombosis

Substanzen

Antibodies, AntiphospholipidAntigens, CD19CD19 molecule, humanReceptors, Chimeric Antigen

Autor:innen und Institutionen

  • Division of Hematology and Hemostaseology, Department of Medicine I, Medical University of Vienna, Vienna, Austria.
  • Division of Hematopoietic Stem Cell Transplantation Unit, Department of Medicine I, Medical University of Vienna, Vienna, Austria.
  • Department of Pathology, Medical University of Vienna, Vienna, Austria.
  • Institute of Immunology, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria.
  • Department of Transfusion Medicine and Cell Therapy, Medical University of Vienna, Vienna, Austria.
  • Division of Hematology and Hemostaseology, Department of Medicine I, Medical University of Vienna, Vienna, Austria. Electronic address: cihan.ay@meduniwien.ac.at.

Förderung

  • Horizon 2020
  • Innovative Medicines Initiative
  • European Federation of Pharmaceutical Industries and Associations
  • Horizon 2020 Framework Programme
  • European Union

Zitieren

APA

Friedberg, E., Wohlfarth, P., Schiefer, A. I., Skrabs, C., Pickl, W. F., Worel, N., Staber, P., Jäger, U., & Ay, C. (2025). Disappearance of antiphospholipid antibodies after anti-CD19 chimeric antigen receptor T-cell therapy of B-cell lymphoma in a patient with systemic lupus erythematosus and antiphospholipid syndrome. Journal of Thrombosis and Haemostasis. https://doi.org/10.1016/j.jtha.2024.09.024

Vancouver

Friedberg E, Wohlfarth P, Schiefer AI, Skrabs C, Pickl WF, Worel N, et al. Disappearance of antiphospholipid antibodies after anti-CD19 chimeric antigen receptor T-cell therapy of B-cell lymphoma in a patient with systemic lupus erythematosus and antiphospholipid syndrome. Journal of Thrombosis and Haemostasis. 2025. doi:10.1016/j.jtha.2024.09.024

BibTeX
@article{Friedberg2025,
  author = {Friedberg, Eleonora and Wohlfarth, Philipp and Schiefer, Ana Iris and Skrabs, Cathrin and Pickl, Winfried Franz and Worel, Nina and Staber, Philipp and Jäger, Ulrich and Ay, Cihan},
  title = {Disappearance of antiphospholipid antibodies after anti-CD19 chimeric antigen receptor T-cell therapy of B-cell lymphoma in a patient with systemic lupus erythematosus and antiphospholipid syndrome},
  journal = {Journal of Thrombosis and Haemostasis},
  year = {2025},
  doi = {10.1016/j.jtha.2024.09.024}
}
Kostenlos starten →